Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ - ETF AI Analysis
Top Page
Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ)
PRFZ, the Invesco FTSE RAFI US 1500 Small-Mid ETF, earns its rating largely thanks to strong, growth-focused holdings like Dynatrace, Paycom, SharkNinja, Manhattan Associates, and Halozyme, which show solid financial performance, positive earnings calls, and strategic growth initiatives. The fund’s score is held back somewhat by weaker names such as Cracker Barrel and 10x Genomics, where declining profitability and revenue challenges are concerns, and by a common risk across several holdings: bearish technical trends and valuation pressures that could increase volatility for investors.
PRFZ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.68B
- Region
- North America
- Expense Ratio
- 0.36%
- Beta
- 1.02
- Issuer
- Invesco
- Inception Date
- Sep 20, 2006
- Dividend Yield
- 0.84%
- Asset Class
- Equity
- Index Tracked
- RAFI Fundamental Select US 1500 Index
PRFZ Summary
PRFZ is an ETF that follows the RAFI Fundamental Select US 1500 Index, focusing on small and mid-sized U.S. companies. It spreads your money across many sectors, including technology, health care, financials, and industrials, giving you broad exposure beyond the big-name large caps. Well-known holdings include DocuSign and Paycom, along with many other smaller firms that may have room to grow. Someone might invest in PRFZ to seek long-term growth and diversification across many smaller companies in the U.S. market. A key risk is that small and mid-cap stocks can be more volatile, so the ETF’s value can go up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.36%, which means you’ll pay about $3.60 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because it uses a more complex, rules-based fundamental strategy rather than simple market-cap weighting.
What would affect this ETF?
PRFZ could benefit if the U.S. economy stays healthy and small- and mid-sized companies in technology, health care, and industrials continue to grow, since the fund focuses on these sectors and uses a fundamentals-based approach that can reward profitable businesses over time. On the downside, rising interest rates, an economic slowdown in the U.S., or tighter regulations on tech and health care firms could hurt many of its holdings, while smaller companies in cyclical areas like consumer and energy may be more volatile during market stress.
PRFZ Top 10 Holdings
PRFZ leans heavily into U.S. small and mid-cap innovators, with rising names like Paycom, DocuSign, and Dynatrace helping power the fund from the tech side, while Halozyme and GRAIL add some punch from health care. 10x Genomics has been more of a roller coaster, strong over the year but recently mixed, and Iovance is clearly lagging, acting as a brake on performance. Cracker Barrel is also losing steam, reflecting pressure on consumer names. Overall, the ETF is U.S.-focused, tilted toward tech and health care, with a few energy and consumer names rounding out the mix.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| SharkNinja, Inc. | 0.49% | $12.82M | $31.92B | 138.97% | 76Outperform | |
| DocuSign | 0.43% | $11.17M | $14.51B | 11.50% | 71Outperform | |
| Paycom | 0.42% | $10.95M | $10.72B | 42.66% | 76Outperform | |
| Roivant Sciences | 0.36% | $9.49M | $29.84B | 94.57% | 58Neutral | |
| Cracker Barrel | 0.36% | $9.29M | $1.46B | 123.82% | 55Neutral | |
| Manhattan Associates | 0.35% | $9.07M | $14.95B | 45.96% | 75Outperform | |
| Crescent Energy Company Class A | 0.35% | $9.02M | $4.71B | 24.33% | 66Neutral | |
| Bio-Techne | 0.34% | $8.96M | $11.44B | 26.73% | 64Neutral | |
| Iridium Communications | 0.34% | $8.96M | $4.90B | 179.75% | 71Outperform | |
| H&R Block | 0.34% | $8.84M | $6.25B | 6.92% | 63Neutral |
PRFZ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRFZ, the sentiment is Positive. The current price of 53.09 is above the 20-day moving average (MA) of 52.88, above the 50-day MA of 53.09, and above the 200-day MA of 51.40, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.49 is Neutral, neither overbought nor oversold. The STOCH value of 49.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRFZ.
PRFZ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $53.10 | $56.00(5.47% Upside) | $2.68B | 0.36% | 66Neutral | |
| $31.70 | $39.13(23.45% Upside) | $3.69B | 0.51% | 66Neutral | |
| $42.37 | $51.74(22.11% Upside) | $3.30B | 0.55% | 68Neutral | |
| $75.03 | $87.55(16.68% Upside) | $2.96B | 0.24% | 66Neutral | |
| $50.24 | $58.54(16.52% Upside) | $2.42B | 0.15% | 70Neutral | |
| $106.56 | $121.96(14.45% Upside) | $1.81B | 0.29% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRFZ | Invesco FTSE RAFI US 1500 Small-Mid ETF | 53.09 | 8.05 | 17.88% | |
| CGMM | Capital Group U.S. Small and Mid Cap ETF | 31.70 | 3.41 | 12.07% | |
| TMSL | T. Rowe Price Small-Mid Cap ETF | 42.37 | 7.27 | 20.71% | |
| JMEE | JPMorgan Market Expansion Enhanced Equity ETF | 75.03 | 11.67 | 18.43% | |
| FSMD | Fidelity Small-Mid Multifactor ETF | 50.24 | 7.04 | 16.31% | |
| USVM | VictoryShares USAA MSCI USA Small Cap Value Momentum ETF | 106.56 | 18.14 | 20.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
